HPV Vaccine Nearly Eliminates Cervical Cancer Deaths in Young Women
Women vaccinated against HPV during early adolescence face a near-zero risk of dying from cervical cancer before age 30, according to a study by Queen Mary University of London (QMUL) published in The Lancet. The research indicates the vaccine has already prevented nearly 200 deaths among young women in England since its introduction.
The analysis, funded by Cancer Research UK, used official cancer death and vaccination data for women aged 20 to 34. Researchers found substantial decreases in mortality for those vaccinated after the vaccine’s 2008 introduction, while mortality remained largely unchanged for those who were never vaccinated.
Why is the HPV vaccine effective against cervical cancer?
High-risk strains of the human papillomavirus (HPV) are responsible for 99% of all cervical cancer cases, which the World Health Organization (WHO) ranks as the fourth most common cancer in women. The vaccine prevents approximately 90% of these cases.
The level of protection depends largely on when the vaccine is administered. According to the QMUL study, girls vaccinated at age 12 or 13 have a near-zero probability of dying from the disease before 30. For women vaccinated between ages 30 and 34, the relative risk of death is 63% lower.
What happens if vaccination rates continue to drop?
Vaccination rates were approaching WHO targets before the pandemic but have since declined. National coverage in England has fallen to 75%, with the rate in London dropping to 60%.
Professor Peter Sasieni of QMUL warns that these trends could reverse previous gains. He estimates that without urgent efforts, 15 to 25 avoidable deaths could occur annually among young women, potentially reaching 200 preventable deaths per year.
Helen Hyndman of The Eve Appeal notes that current rates may push the goal of eradicating cervical cancer back from 2024 to as late as 2050. This suggests a significant delay in health outcomes if screening and vaccination rates don’t improve.
How are health systems addressing these gaps?
The NHS aims to eliminate cervical cancer by 2040 through a combination of vaccination and screening. To reach this, the British Department of Health and Social Care is expanding access via community pharmacies for those who missed school-based doses.
Health officials are also deploying HPV self-testing kits to women who do not attend traditional screenings. This strategy aims to detect cancer in early stages when treatment is most effective.
In Romania, the government provides 100% compensation for the HPV vaccine for girls and boys aged 11 to 26. Women between 27 and 45 years old receive 50% compensation for the vaccine.
Global Targets for 2030
- Vaccinate 90% of girls by age 15.
- Screen 70% of women.
- Treat 90% of women with cervical conditions.
What may happen next?
Public health officials may increase targeted measures to reach communities with the lowest vaccination rates. According to Michelle Mitchell of Cancer Research UK, urgent government intervention is essential to address these specific areas.
If vaccination and screening rates are restored to pre-pandemic levels, the incidence of cervical cancer could potentially drop to a point where almost no one develops the disease, according to Professor Sasieni.
Frequently Asked Questions
Who is eligible for free HPV vaccination in Romania?
The vaccine is 100% compensated for girls and boys between the ages of 11 and 26.
What other cancers does the HPV vaccine protect against?
The vaccine protects against certain types of cancer involving the anus, penis, vagina, vulva, mouth, and throat, as well as genital warts.
What is the current vaccination rate in London?
According to Professor Peter Sasieni, the current vaccination rate in London is 60%.
Do you believe community-based vaccination clinics are the best way to increase healthcare access?